Introduction {#s1}
============

Major depressive disorder (MDD), also termed as clinical/unipolar depressive disorder, affects more than 264 million people worldwide. It is considered to be the most common psychiatric/mental disorder and is characterized by complex and widely various physical, psychological, and behavioral symptoms in individuals (especially for adolescent and elderly groups) ([@B1]). Epidemiological investigations reported the life-time prevalence of MDD in different countries, such as the United States, 16.2% ([@B2]), Canada, 11.3% ([@B3]), and China, 3.4% ([@B4]), with considerable regional variation. As a chronic mental disorder, MDD exerts a substantial burden on patients (e.g., cognitive impairment, premature mortality, and even suicide) ([@B5], [@B6]), their families (e.g., physical and economic burden) ([@B7]), and society (e.g., the economic burden of MDD in US is estimated to exceed \$210 billion) ([@B8]). Moreover, it is reported that psychiatric disorders account for 22.8% of the global burden of disease, among which MDD is the main cause of disability, and this proportion will increase along with population growth and ageing ([@B9]). World Health Organization (WHO) has ranked MDD as the second leading cause of disability globally, and predicts it to be one of the top three leading causes of disease burden in high-income countries by 2030, second only to HIV/AIDS ([@B10]).

In the early 20^th^ century, the term "psychopharmacology" started to emerge, and it was not until the 1950s and 1960s that exploration and clinical implementation of medicinal antidepressants occurred, respectively ([@B11]). Evidence shows that successful antidepressant treatment is one of the most effective ways of reducing disability, preventing morbidity, and improving quality of life (QOL) for patients with MDD ([@B12]). However, due to the complex etiology and pathogenesis of depressive disorders, the mechanism of action of antidepressants are mostly based on the monoamine hypothesis mainly involving serotonin, norepinephrine, and dopamine and its receptor ([@B13]). At present, more than 30 antidepressant drugs are available around the world, of which at least 20 are regularly taken by adult patients with depressive disorders ([@B14]). Categories of antidepressant drugs commonly used in clinic are first generation antidepressant drugs developed during the "golden decade" of psychopharmacology in the 1950s, and mainly included tricyclic antidepressants and monoamine oxidase inhibitors. Second generation antidepressant drugs, developed in the late 1980s and early 1990s, are generally considered to be the new generation of clinical treatment for MDD and are represented by selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) ([@B11]).

In addition, given that a significant number of patients fail to respond to the existing above-mentioned antidepressant agents, the development and application of atypical antidepressants ([@B15]), phytochemicals ([@B16]), and new drug therapeutic targets ([@B17]), as well as the combination of medication and other psychotherapy (e.g., cognitive behavior therapy) ([@B18]) have become one of the important research directions in the treatment of depressive disorder. Moreover, based on the utilization of antidepressant drugs, scholars also compared the clinical treatment effectiveness by employing outcome indicators, such as acceptability, efficacy, tolerance, adverse reactions, and changes in brain structure and function ([@B19]--[@B21]).

Thus, scholars utilized MDD and drug therapy as a research subject to carry out large numbers of clinical and basic studies, which provided significant results. At the same time, the quality of papers published in influential journals increased, and the publications showed an increasing trend year by year. This increase in publications in turn caused scholars to begin to devote more energy analyzing the current frontiers and research hotspots in their own respective fields. The term "bibliometrics" was first proposed by the British scholar Pritchard in 1969 ([@B22]), which was defined as "that knowledge structure and development could be generated and organized through information processing by combining mathematical and statistical methods" ([@B23], [@B24]). With the gradual maturity of bibliometrics research, its application has been expanded to many fields, such as social ([@B25]) and medical sciences ([@B26]). Moreover, according to carry out scientific and standardized management, as well as bibliometric, citation, and quantitative analysis of the information resources, scholars understand the current status and dynamic trends of the related discipline or research field. Co-word analysis, as a significant branch of bibliometric analysis, first appeared in the 1970s and was elaborated in the article written by Callon ([@B27]). Statistical methods in co-word analysis are mostly related to social network analysis (SNA), clustering analysis, and strategic diagram.

Here, we comprehensively adopt the methods of co-word analysis to conduct quantitative statistical analysis and qualitative standardized discussion on publications related to drug therapy studies on MDD from 2001 to 2018, and aim to gain insights into hotspots, knowledge structure, and theme trends in this field, as well as to guide clinicians and researchers to address clinical treatment and basic research gaps.

Methods {#s2}
=======

Data Sources and Bibliographic Matrix Setup {#s2_1}
-------------------------------------------

PubMed, as a free search engine and a part of the Entrez information retrieval system, was developed by National Center for Biotechnology Information of the National Library of Medicine in 2000. It provides a database of biomedical manuscript and abstract searches, with the central theme of medicine, but also other medically related fields by employing search strategies of Medical Subject Headings (MeSH) and text-word searches. MeSH is a typical normative language, which standardizes synonyms of the same concept to ensure the correspondence between words and concepts. In the actual implementation of the retrieval strategy, the application of MeSH retrieval can effectively improve the recall ratio and precision ratio of the retrieval results.

In this study, publications used in bibliometric analyses were retrieved and downloaded from PubMed by employing the retrieval strategy of \[Search (((("Depressive Disorder, Major"\[MeSH\]) OR "Major depressive disorder"\[Title/Abstract\]) OR "MDD"\[Title/Abstract\])) AND (("Drug therapy"\[MeSH\]) OR "Antidepressive Agents" \[MeSH\]) Filters: Journal Article\[article type\]\]. In addition, in order to dynamically analyze the changes in high frequency major MeSH terms/MeSH subheadings and to develop trends and changes of knowledge structure for drug therapy studies on MDD, the publication data were divided into three periods, including January 1, 2001 to December 31, 2006, January 1, 2007 to December 31, 2012, and January 1, 2013 to December 31, 2018. Analysis parameters, including distribution of countries, titles of the periodicals and papers, publication quantity, and publication years, as well as author names and keywords, were accurately extracted, downloaded and properly saved in an XML format. The literature screening was completed by two researchers independently by evaluating and excluding irrelevant articles. The concordance rate (the value of Kappa coefficient) between them was 0.95, indicating a strong agreement ([@B28]). The inclusion criteria for articles were all studies must be primarily focus on drug therapy for MDD; article type was classified as journal article. Exclusion criteria were: studies which take "bipolar disorder" as major MeSH terms and "therapy, drug therapy, pathology, physiopathology, blood, genetics" as MeSH subheadings; publication time was not during the retrieval time limit; published as editorial, comments, or conference paper. Ultimately, 1,577, 2,680, 2,848 articles were included in each period and were used to complete the subsequently statistics.

H-index was first proposed by Jorge Hirsch ([@B29]) to quantify the work of individual researchers, and was gradually expanded to evaluate the influence of patents ([@B30]), academic journals ([@B31]), research institutions ([@B32]), and bibliometric analysis ([@B33]). Its original definition was expounded by incorporating both quantity and quality; "A scientist has index *h* if *h* of his or her *N~p~* papers has at least *h* citations each and the other (*N~p~-h*) papers have ≤ *h* citation each" where *N~p~* stands for the number of papers published over *n* years.

In the current study, we use the above concept to implement a number of steps: ① Bibliographic information, such as major MeSH terms and major MeSH subheadings were extracted by employing the bibliographic item co-occurrence matrix system (BICOMBS) ([@B34]). ② According to word frequency statistics, major MeSH terms/MeSH subheadings were arranged in descending order. When the word frequency of the MeSH terms is the same as its rank number, then this number is the threshold value of high- and low-frequency major MeSH terms/MeSH subheadings. In reality, the MeSH terms' rank number is not always the same as its frequency, and we often take the MeSH term(s) whose occurrence frequency is one less than the rank of the high-frequency Mesh terms so as not to overlook them.

In addition, matrices of the term-source literature and the term-term co-occurrence were generated by the bibliographic item co-occurrence matrix system to prepare for bi-clustering, strategic diagram, and social network analyses.

Bi-Clustering Analysis of High-Frequency MeSH Terms/MeSH Subheadings {#s2_2}
--------------------------------------------------------------------

Bi-clustering, also known as co-clustering, bi-dimensional clustering, two-way clustering, or subspace clustering, was introduced by Hartigan in 1970s ([@B35]). It refers to simultaneously clustering rows and columns of a data matrix. In recent years, it has been widely used to implement data analysis in the fields, including gene expression ([@B36]) and cancer immunotherapy ([@B37]). After co-word analysis of these extracted high-frequency major MeSH terms/MeSH subheadings, we inputted three matrices of term-source literature into gCLUTO 1.0 (Graphical Clustering Toolkit, Version 1.0, which was designed as a graphical front-end for the CLUTO data clustering library by Rasmussen, et al.) ([@B38]) for bi-clustering analysis by setting the parameters as repeated bisection for clustering, cosine function for similarity calculation, and I^2^ for clustering standard function.

In addition, representative literature that contributes to the formation of the clusters can be extracted by two parameters, including descriptive (literatures that represents this class of characteristics) and discriminating (literature that distinguishes it from other clusters) features. Moreover, we can also trace the original literature from the PubMed database on the basis of their PubMed Unique Identifier, which was extracted by gCLUTO and were significant for analyzing and summarizing the content of each cluster.

Strategic Diagram Analysis {#s2_3}
--------------------------

In 1988, Law et al. ([@B39]) firstly proposed the statistical analysis method of strategic diagram. As a significant branch of co-word analysis, it is mainly used to describe the internal relations and mutual influences so as to further predict the theme trends in a certain research field. After more than 30 years of development, strategic diagram has been applied in various disciplines, such as information science ([@B40]), higher education ([@B41]), and medicine ([@B42]), among others. As seen in [**Figure 6(i)**](#f6){ref-type="fig"}, strategic diagram is a two-dimensional coordinate axis, in which X-axis represents centrality, indicating the intensity of the interaction between clusters, and Y-axis represents density, indicating the strength of the connections of hotspots within a theme cluster ([@B43]). In general, the two above indices can be calculated on the basis of a term-term matrix. In addition, according to the coordinate position of each cluster in the strategic diagram, we can analyze its development and evolution trend.

In the specific implementation of statistical analysis, GraphPad Prism 5.0 software (GraphPad, Inc., La Jolla, CA, USA) was employed to plot a strategic diagram in each period from 2001 to 2018.

Social Network Analysis {#s2_4}
-----------------------

SNA originated in early 20^th^ century and refers to a method of studying social interactions and the structure of these interactions among social factors (e.g., individuals, groups and organizations) ([@B44]). Though it has been widely applied in the field of sociology as a paradigm of social science research, it is now used across multiple disciplines ([@B45], [@B46]), including organizational psychology, biology, and communications.

In this study, the SNA was built for each period to explore the knowledge structure and to predict the theme trends of drug therapy studies on MDD on the basis of construction of a term-term co-occurrence matrix. All calculations concerning the SNA were carried out by using UCINET Version 6.0 (University of California at Irvine Network, Version 6.0), which is a software tool for analysis and visualization of exploratory data network and belongs to Analytic Technologies Co. (Nicholasville, Kentucky, USA). The visualization of the network structure was demonstrated by employing NetDraw 2.084 software, which was developed by Steve Borgatti (<http://www.analytictech.com/downloadnd.htm>). In addition, to objectively evaluate the importance of each node within the SNA in each period, three involved centrality parameters were computed and analyzed as follows:

1.  \- *Degree centrality* is arguably the simplest conceptually and can be used to measure how well-connected a given node is, in other words, it can be obtained by calculating how many direct connections the given node has with others within a network ([@B47]). Nodes with higher value of degree centrality have agonistic interaction with many other nodes, thus, it is suitable for evaluating the co-occurrence level among nodes.

2.  \- *Betweenness centrality* can be used to measures the extent to which the given node lies on the shortest paths between two other nodes of a network. Nodes with higher value of betweenness centrality are important for controlling the connections within a network, especially if they serve as a bridge or cut point between two network components ([@B48]).

3.  \- *Closeness centrality* can be used to evaluate how close the given node is to all other nodes in a network. The calculation process of this centrality parameter is based on the inverse of the shortest path lengths between the given node and other nodes within a network. That is, the more central the given node is, the larger its closeness centrality value and the closer it is to all the other nodes ([@B44]).

Considering that betweenness centrality is more suitable for describing the decisive role in the whole network, we selected it to scale the size of the nodes in the SNA.

The flowchart of this bibliometric research can be seen in [**Figure 1**](#f1){ref-type="fig"}.

![The flowchart of this bibliometric research. MDD, major depressive disorder; BICOMS, the bibliographic item co-occurrence matrix system. The contents in parentheses refer to software used to perform the targeted statistical analysis. Matrices constructed by BICOMBS include the term-source literature matrix and the term-term cooccurrence matrix.](fpsyt-11-00647-g001){#f1}

Results {#s3}
=======

Distribution Characteristics of Related Publications {#s3_1}
----------------------------------------------------

As can be seen from [**Figure 2**](#f2){ref-type="fig"}, the number of related articles that used MDD and drug therapy as the research subjects and had been published in PubMed was 1,577, 2,680, 2,848 from the three periods during 2001--2006, 2007--2012, and 2013--,2018, respectively, which showed a gradually increasing publication tendency. According to comparative statistical analysis by source of countries, journals, and the first author as the main statistical indices, we found that the total proportion of publications of the top five countries was 86.209%, 86.431%, and 84.027% during the three time-periods, respectively. The U.S., England, the Netherlands, and Germany were the top four countries in descending order of number of publications during each time-period ([**Table 1**](#T1){ref-type="table"}). Although France ranked fifth during 2001--2006, it was replaced by Ireland during the next two time-periods. Additionally, the proportion of publications in the U.S. has been trending downward, while in England and the Netherlands it has been increasing. Another important result was that *The Journal of Clinical Psychiatry* and *Journal of Affective Disorders* were first and second, respectively, in the number and proportion of publications during 2001--2006 and 2007--2012, but this order was reversed during 2013--2018. In addition, *Fava M* has been the author who contributed the most research papers to the research field of MDD and drug therapy during the three time-periods studied, although the number and proportion of his publications decreased during each successive time-period.

![The number of publications of drug therapy studies on major depressive disorder in PubMed from 2001 to 2018.](fpsyt-11-00647-g002){#f2}

###### 

Temporal distribution of publications of drug therapy studies on major depressive disorder in PubMed since the 21^st^ century.

  Period      Rank          Country          Top journal                                                      Author                                                                 
  ----------- ------------- ---------------- ---------------------------------------------------------------- -------------------------------------- --------------- --------------- --------------
  2001-2006   1             United States    798 (46.831%)                                                    *The Journal of clinical psychiatry*   170 (9.971%)    Fava M          90 (5.282%)
  2           England       419 (24.589%)    *Journal of affective disorders*                                 89 (5.220%)                            Thase ME        52 (3.052%)     
  3           Netherlands   124 (7.277%)     *Biological psychiatry*                                          64 (3.754%)                            Rush AJ         51 (2.993%)     
  4           Germany       81 (4.754%)      *Journal of clinical psychopharmacology*                         53 (3.109%)                            Nierenberg AA   48 (2.817%)     
  5           France        47 (2.758%)      *The American journal of psychiatry*                             43 (2.522%)                            Trivedi MH      39 (2.289%)     
  Total                     1469 (86.209%)                                                                    419 (24.576%)                                          280 (16.433%)   
  2007-2012   1             United States    1235 (42.748%)                                                   *The Journal of clinical psychiatry*   220 (7.613%)    Fava M          111 (3.842%)
  2           England       785 (27.172%)    *Journal of affective disorders*                                 217 (7.509%)                           Thase ME        78 (2.700%)     
  3           Netherlands   316 (10.938%)    *Depression and anxiety*                                         65 (2.250%)                            Trivedi MH      77 (2.665%)     
  4           Germany       90 (3.115%)      *International clinical psychopharmacology*                      62 (2.145%)                            Rush AJ         62 (2.146%)     
  5           Ireland       71 (2.458%)      *Progress in neuro-psychopharmacology & biological psychiatry*   57 (1.972%)                            Papakostas GI   56 (1.938%)     
  Total                     2497 (86.431%)                                                                    621 (21.489%)                                          384 (13.291%)   
  2013-2018   1             United States    1023 (34.294%)                                                   *Journal of affective disorders*       285 (9.545%)    Fava M          60 (2.011%)
  2           England       942 (31.579%)    *The Journal of clinical psychiatry*                             132 (4.421%)                           McIntyre RS     59 (1.978%)     
  3           Netherlands   443 (14.851%)    *Journal of psychiatric research*                                72 (2.411%)                            Thase ME        53 (1.777%)     
  4           Germany       108 (3.621%)     *The international journal of neuropsychopharmacology*           60 (2.009%)                            Trivedi MH      49 (1.643%)     
  5           Ireland       80 (2.682%)      *Psychiatry research*                                            58 (1.942%)                            Zarate CA       48 (1.609%)     
  Total                     2596 (84.027%)                                                                    607 (20.328%)                                          269 (9.018%)    

Research Hotspots and Theme Clusters of Drug Therapy Studies on MDD {#s3_2}
-------------------------------------------------------------------

In this study, 29, 35, and 36 high-frequency major MeSH terms/MeSH subheadings were extracted based on bibliographic statistical analysis from the periods during 2001--2006, 2007--2012, and 2013--2018, respectively. Further analysis demonstrated that the total percentages of their cumulative frequency were 43.6771%, 44.3149%, and 43.0717%, respectively, and that these extracted high-frequency major MeSH terms/MeSH subheadings could be identified as the research hotspots of drug therapy studies on MDD in every 6-year period from 2001 to 2018 ([**Tables 2**](#T2){ref-type="table"}--[**4**](#T4){ref-type="table"}).

###### 

Distribution of the high-frequency major MeSH terms/MeSH subheadings of drug therapy studies on major depressive disorder in PubMed from 2001 to 2006.

  Rank number   Major MeSH terms/ MeSH subheadings                           Frequency   Percentage (%)   Cumulative percentage (%)
  ------------- ------------------------------------------------------------ ----------- ---------------- ---------------------------
  1             Depressive Disorder, Major / drug therapy                    810         10.4949          10.4949
  2             Antidepressive Agents / therapeutic use                      554         7.1780           17.6730
  3             Depressive Disorder, Major / therapy                         205         2.6561           20.3291
  4             Serotonin Uptake Inhibitors / therapeutic use                200         2.5913           22.9204
  5             Antidepressive Agents, Second-Generation / therapeutic use   180         2.3322           25.2527
  6             Depressive Disorder / drug therapy                           156         2.0212           27.2739
  7             Antidepressive Agents, Tricyclic / therapeutic use           100         1.2957           28.5696
  8             Depressive Disorder, Major / diagnosis                       98          1.2698           29.8393
  9             Depressive Disorder, Major / psychology                      86          1.1143           30.9536
  10            Depressive Disorder, Major / epidemiology                    75          0.9718           31.9254
  11            Citalopram / therapeutic use                                 73          0.9458           32.8712
  12            Fluoxetine / therapeutic use                                 72          0.9329           33.8041
  13            Antidepressive Agents / adverse effects                      68          0.8811           34.6852
  14            Cyclohexanols / therapeutic use                              64          0.8292           35.5144
  15            Antidepressive Agents / administration & dosage              63          0.8163           36.3307
  16            Paroxetine / therapeutic use                                 55          0.7126           37.0433
  17            Sertraline / therapeutic use                                 49          0.6349           37.6782
  18            Antidepressive Agents / pharmacology                         49          0.6349           38.3130
  19            Depressive Disorder, Major / metabolism                      47          0.6090           38.9220
  20            Depressive Disorder, Major / physiopathology                 44          0.5701           39.4921
  21            Antipsychotic Agents / therapeutic use                       44          0.5701           40.0622
  22            Depressive Disorder, Major / blood                           38          0.4924           40.5545
  23            Anxiety Disorders / drug therapy                             38          0.4924           41.0469
  24            Depressive Disorder, Major / complications                   37          0.4794           41.5263
  25            Depressive Disorder, Major / etiology                        36          0.4664           41.9927
  26            Thiophenes / therapeutic use                                 34          0.4405           42.4333
  27            Depressive Disorder, Major / genetics                        33          0.4276           42.8608
  28            Mianserin / analogs & derivatives                            33          0.4276           43.2884
  29            Depressive Disorder / therapy                                30          0.3887           43.6771

###### 

Distribution of the high-frequency major MeSH terms/MeSH subheadings of drug therapy studies on major depressive disorder in PubMed from 2007 to 2012.

  Rank number   Major MeSH terms/ MeSH subheadings                           Frequency   Percentage (%)   Cumulative percentage (%)
  ------------- ------------------------------------------------------------ ----------- ---------------- ---------------------------
  1             Depressive Disorder, Major / drug therapy                    1470        11.0543          11.0543
  2             Antidepressive Agents / therapeutic use                      1078        8.1065           19.1608
  3             Depressive Disorder, Major / therapy                         364         2.7373           21.8980
  4             Antidepressive Agents, Second-Generation / therapeutic use   253         1.9025           23.8006
  5             Serotonin Uptake Inhibitors / therapeutic use                207         1.5566           25.3572
  6             Depressive Disorder, Major / psychology                      174         1.3085           26.6657
  7             Citalopram / therapeutic use                                 173         1.3009           27.9666
  8             Depressive Disorder, Major / diagnosis                       151         1.1355           29.1021
  9             Depressive Disorder, Major / epidemiology                    143         1.0753           30.1775
  10            Depressive Disorder, Major / genetics                        131         0.9851           31.1626
  11            Antidepressive Agents / pharmacology                         126         0.9475           32.1101
  12            Cyclohexanols / therapeutic use                              122         0.9174           33.0275
  13            Antidepressive Agents / adverse effects                      118         0.8874           33.9149
  14            Depressive Disorder / drug therapy                           110         0.8272           34.7421
  15            Depressive Disorder, Major / physiopathology                 109         0.8197           35.5617
  16            Antipsychotic Agents / therapeutic use                       105         0.7896           36.3513
  17            Antidepressive Agents / administration & dosage              97          0.7294           37.0808
  18            Thiophenes / therapeutic use                                 95          0.7144           37.7952
  19            Fluoxetine / therapeutic use                                 86          0.6467           38.4419
  20            Depressive Disorder, Major / blood                           69          0.5189           38.9607
  21            Piperazines / therapeutic use                                62          0.4662           39.4270
  22            Antidepressive Agents, Tricyclic / therapeutic use           60          0.4512           39.8782
  23            Depressive Disorder, Major / complications                   55          0.4136           40.2918
  24            Sertraline / therapeutic use                                 54          0.4061           40.6978
  25            Depressive Disorder, Major / metabolism                      54          0.4061           41.1039
  26            Mianserin / analogs & derivatives                            51          0.3835           41.4874
  27            Depression / drug therapy                                    51          0.3835           41.8710
  28            Cognitive Behavioral Therapy                                 48          0.3610           42.2319
  29            Serotonin Uptake Inhibitors / adverse effects                45          0.3384           42.5703
  30            Depressive Disorder, Major / pathology                       41          0.3083           42.8786
  31            Anxiety Disorders / drug therapy                             41          0.3083           43.1869
  32            Cognitive Behavioral Therapy / methods                       39          0.2933           43.4802
  33            Paroxetine / therapeutic use                                 38          0.2858           43.7660
  34            Antidepressive Agents, Second-Generation / adverse effects   37          0.2782           44.0442
  35            Psychotherapy / methods                                      36          0.2707           44.3149

###### 

Distribution of the high-frequency major MeSH terms/MeSH subheadings of drug therapy studies on major depressive disorder in PubMed from 2013 to 2018.

  Rank number   Major MeSH terms/ MeSH subheadings                           Frequency   Percentage (%)   Cumulative percentage (%)
  ------------- ------------------------------------------------------------ ----------- ---------------- ---------------------------
  1             Depressive Disorder, Major / drug therapy                    1433        10.1986          10.1986
  2             Antidepressive Agents / therapeutic use                      1206        8.5830           18.7816
  3             Depressive Disorder, Major / therapy                         368         2.6190           21.4006
  4             Antidepressive Agents / pharmacology                         242         1.7223           23.1229
  5             Depressive Disorder, Major / psychology                      193         1.3736           24.4965
  6             Depressive Disorder, Major / diagnosis                       157         1.1174           25.6138
  7             Depression / drug therapy                                    154         1.0960           26.7098
  8             Serotonin Uptake Inhibitors / therapeutic use                147         1.0462           27.7560
  9             Antidepressive Agents, Second-Generation / therapeutic use   144         1.0248           28.7809
  10            Citalopram / therapeutic use                                 136         0.9679           29.7488
  11            Antidepressive Agents / administration & dosage              133         0.9466           30.6953
  12            Depressive Disorder, Major / genetics                        132         0.9394           31.6348
  13            Depressive Disorder, Treatment-Resistant / drug therapy      128         0.9110           32.5457
  14            Depressive Disorder, Major / physiopathology                 118         0.8398           33.3855
  15            Antidepressive Agents / adverse effects                      109         0.7757           34.1613
  16            Depressive Disorder, Major / metabolism                      91          0.6476           34.8089
  17            Antipsychotic Agents / therapeutic use                       89          0.6334           35.4423
  18            Depressive Disorder, Major / blood                           81          0.5765           36.0188
  19            Depressive Disorder, Major / epidemiology                    78          0.5551           36.5739
  20            Piperazines / therapeutic use                                73          0.5195           37.0934
  21            Depressive Disorder / drug therapy                           72          0.5124           37.6059
  22            Depressive Disorder, Major / complications                   70          0.4982           38.1040
  23            Ketamine / therapeutic use                                   68          0.4840           38.5880
  24            Brain / drug effects                                         60          0.4270           39.0150
  25            Cognitive Behavioral Therapy / methods                       59          0.4199           39.4349
  26            Sertraline / therapeutic use                                 57          0.4057           39.8406
  27            Depressive Disorder, Major / pathology                       51          0.3630           40.2035
  28            Ketamine / pharmacology                                      51          0.3630           40.5665
  29            Fluoxetine / therapeutic use                                 49          0.3487           40.9152
  30            Outcome Assessment (Health Care)                             48          0.3416           41.2569
  31            Sulfides / therapeutic use                                   46          0.3274           41.5842
  32            Depressive Disorder, Treatment-Resistant / therapy           46          0.3274           41.9116
  33            Depression / therapy                                         44          0.3131           42.2248
  34            Cyclohexanols / therapeutic use                              43          0.3060           42.5308
  35            Psychotherapy / methods                                      40          0.2847           42.8155
  36            Suicidal Ideation                                            36          0.2562           43.0717

After completing bi-clustering analysis, three, four, and five theme clusters were obtained based on actual clustering effects and researchers' professional knowledge in the research field of MDD and drug therapy, and a visual matrix and visual mountain of three different periods were generated ([**Figures 3**](#f3){ref-type="fig"}--[**5**](#f5){ref-type="fig"}).

![Bi-clustering analysis of 29 high-frequency MeSH terms/MeSH subheadings and literatures of drug therapy studies on major depressive disorder in 2001--2006. ①Matrix visualization of bi-clustering of 29 high-frequency major MeSH terms/MeSH subheadings and PubMed unique identifiers of literatures. ②Mountain visualization of bi-clustering of 29 high-frequency major MeSH terms/MeSH subheadings and literatures.](fpsyt-11-00647-g003){#f3}

![Bi-clustering analysis of 35 high-frequency MeSH terms/MeSH subheadings and literatures of drug therapy studies on major depressive disorder in 2007--2012. ①Matrix visualization of bi-clustering of 35 high-frequency major MeSH terms/MeSH subheadings and PubMed unique identifiers of literatures. ②Mountain visualization of bi-clustering of 35 high-frequency major MeSH terms/MeSH subheadings and literatures.](fpsyt-11-00647-g004){#f4}

![Bi-clustering analysis of 36 high-frequency MeSH terms/MeSH subheadings and literatures of drug therapy studies on major depressive disorder in 2013--2018. ①Matrix visualization of bi-clustering of 36 high-frequency major MeSH terms/MeSH subheadings and PubMed unique identifiers of literatures. ②Mountain visualization of bi-clustering of 36 high-frequency major MeSH terms/MeSH subheadings and literatures.](fpsyt-11-00647-g005){#f5}

As for matrix visualization, the color represents values in the original data matrix of term-source literature. Specifically, white stands for near-zero values, while deepening red is indicative of larger values. The rows in the matrix are rearranged so that the rows and columns of the theme cluster are placed together. Black horizontal lines separate these generated clusters in each period. Besides, we also annotated the extracted high-frequency major MeSH terms/MeSH subheadings in each theme cluster on the right side of the matrix ([**Figures 3**](#f3){ref-type="fig"}--[**5**](#f5){ref-type="fig"}), with the serial number before MeSH terms having the same meaning as in [**Tables 2**](#T2){ref-type="table"}--[**4**](#T4){ref-type="table"}.

Within mountain visualization, the shape of each mountain is actually a Gaussian curve, which represents a rough estimate of the distribution of data within each theme cluster. The height and volume of the mountain are proportional to the internal similarity within the cluster, and the number of objects contained in each theme cluster, respectively. Several Gaussian curves are then arranged and superimposed on the basis of bi-clustering statistical results and thus form a mountain visualization. The color of the mountain is proportional to the standard deviation (SD) within each theme cluster. Moreover, only the color of the summit is relevant, where red represents low SD, and blue represents high. The peak of cluster 0 during 2001--2006, cluster 1 during 2007--2012, and cluster 1 and cluster 3 during 2013--2018 are red, indicating that the SD of similarity within the theme clusters is the smallest; that is, the distribution is concentrated.

We further combined contents of the high-frequency major MeSH terms/MeSH subheadings contained in each cluster, the extracted significant representative literature (seen column 5 in [**Table 6**](#T6){ref-type="table"}), and researchers' professional knowledge in the field of drug therapy studies on MDD to interpret meaning and connation of each theme cluster involved during the three time-periods from 2001 to 2018.

Theme Trends of Drug Therapy Studies on MDD {#s3_3}
-------------------------------------------

By defining the baseline (mean and median), the four quadrants of the strategic diagram can be obtained, where each quadrant reflects the development of the theme cluster ([@B49]). As shown in [**Figure 6(i)**](#f6){ref-type="fig"}, clusters in quadrant I have the strongest centrality and density. The clusters are also the core themes of their research field, are closely related to each other, and have been developed due to researchers' extensive attention. Clusters in quadrant II have higher density, but lower centrality, indicating that the hotspots/MeSH terms within the clusters are closely related, but that the relationship with other hotspots/MeSH terms outside the cluster is relatively distant. In quadrant III, the centrality and density of the clusters are both the weakest, representing that they are neither closely related within clusters nor with other external clusters, and they display immaturity in development. Clusters with stronger centrality and lower density in quadrant IV indicate loose internal structure and immature development. However, contents in quadrant IV are closely related to other clusters and topics in the cluster have been actively pursued in the research field, which deserves attention.

![Strategic diagrams for drug therapy studies on major depressive disorder in three different periods. (i) Explanation of the strategic diagram. (ii) Strategic diagram in 2001--2006. (iii) Strategic diagram in 2007--2012. (iv) Strategic diagram in 2013--2018. Clusters in each strategic diagram refer to the bi-clustering results presented in [**Table 7**](#T7){ref-type="table"}. The size of each single node is proportional to the number of high-frequency major MeSH terms/MeSH subheadings involved in each cluster ([**Table 6**](#T6){ref-type="table"}).](fpsyt-11-00647-g006){#f6}

Between 2001--2006, cluster 0 in quadrant II represented the application and therapeutic effect of different types of antidepressant agents, which was considered as peripheral but developed content. Cluster 1 in quadrant IV represented analysis of influencing factors of the therapeutic effect and clinical outcome (e.g., adverse reaction) of antidepressant drugs, which were central, but undeveloped themes. The contents of cluster 2 referred to research on the functional mechanism of antidepressants in pathophysiology, neuroendocrinology, and neurobiochemistry, whose coordinate was in quadrant III, indicating that the related content was considered to be either emerging or in decline, namely on the edge of the research field during that period of time.

Compared with the results of the first period, the causes of adverse reactions of antidepressant agents, which were part of cluster 3, had transferred from quadrant IV in 2001--2006 to quadrant III in 2007--2012. Additionally, other parts of cluster 3 were predictive studies on the effectiveness of antidepressant treatment based on brain imaging, which was a newly developed theme. Cluster 0, located in quadrant II, mainly focused on comparative analysis of the clinical treatment effect and tolerability of antidepressant agents (mainly SSRIs and SNRIs) combined with antipsychotics in patients with depressive disorder, while cluster 1 in quadrant IV focused on analysis of the therapeutic effect of different antidepressant agents (mainly SSRIs) on patients with major depressive disorder, as well as analysis of the effect of different antidepressants on the treatment of patients with MDD comorbid with anxiety. Contents of cluster 2, located in quadrant III, was part of the same as cluster 1 during 2001--2006, but research into the effects of psychotherapy interventions were added to it.

During 2013--2018, cluster 0, which focused on analysis of the therapeutic effect and influencing factors of patients with depressive disorder after receiving psychotherapy alone or combined with drug therapy, was part of the same theme content as cluster 2 (quadrant III) during 2007--2012, but transferred to quadrant II with higher density but lower centrality. Cluster 1, situated in quadrant I, identified as developed and core themes in the past 6 years, represented evaluation of the therapeutic effect of new antidepressants, as well as clinical effects of antipsychotic drugs combined with antidepressant agents. By comparison, we found that the second part of cluster 1, which was the same as cluster 0 (quadrant II) during 2007--2012, whereby, the theme content gradually moved from the peripheral to the core. Moreover, clusters 2, 3, and 4 were situated in quadrant III, and mainly focused on comparative analysis of clinical treatment effects of new antidepressant agents and other SSRIs with genetic/biomarkers that predict the effectiveness of antidepressant therapy; the effects of antidepressant treatment on residual depressive symptoms; the mechanism of action; and clinical therapeutic effects of antidepressant agents.

In brief, these three strategic diagrams clearly revealed the current situation and development tendency of each theme cluster of drug therapy studies on MDD during the three different time-periods.

Knowledge Structure of Drug Therapy Studies on MDD {#s3_4}
--------------------------------------------------

Results of the SNAs of the three periods are presented in [**Figure 7**](#f7){ref-type="fig"}, and the main statistical parameters, such as degree, betweenness, and closeness centrality, were employed to analyze the knowledge structure of drug therapy studies on MDD between 2001 and 2018 ([**Tables 5**](#T5){ref-type="table"} and [**6**](#T6){ref-type="table"}).

![SNA for high-frequency major MeSH terms/MeSH subheadings applied to drug therapy studies on major depressive disorder. (i) SNA for 29 high-frequency major MeSH terms/MeSH subheadings in 2001--2006. (ii) SNA for 35 high-frequency major MeSH terms/MeSH subheadings in 2007--2012. (iii) SNA for 36 high-frequency major MeSH terms/MeSH subheadings in 2013--2018. The size of the nodes and the thickness of the lines within the networks represent centrality of MeSH terms and the co-occurrence frequency of MeSH terms pairs, respectively. Red icons (![](fpsyt-11-00647-i001.jpg)): Node with the highest betweenness centrality. Circle icons: Nodes highly co-occurred with other nodes since the period of 2001--2006 (![](fpsyt-11-00647-i002.jpg)), 2007--2012 (![](fpsyt-11-00647-i003.jpg)) and 2013--2018 (![](fpsyt-11-00647-i004.jpg)), respectively ([**Figure 7**](#f7){ref-type="fig"} (i)--(iii)). Box icons: Emerging nodes in 2001--2006 (![](fpsyt-11-00647-i005.jpg)), 2007--2012 (![](fpsyt-11-00647-i006.jpg)) and 2013--2018(![](fpsyt-11-00647-i007.jpg)), respectively.](fpsyt-11-00647-g007){#f7}

###### 

Descriptive statistics for centrality measures of drug therapy studies on major depressive disorder since the 21^st^ century.

  Period      Density        Degree   Betweenness   Closeness                                                       
  ----------- -------------- -------- ------------- ----------------- ------- -------- ------------- -------- ----- ---------------
  2001-2006   7.096±21.748   23.000   1321          198.690±268.690   0.000   13.055   4.552±3.444   58.333   100   76.702±10.120
  2007-2012   8.886±35.781   32.000   2471          302.114±480.325   0.059   17.598   5.486±4.190   59.649   100   76.886±10.056
  2013-2018   8.357±35.781   52.000   2378          292.500±478.819   0.484   18.869   5.917±4.987   60.345   100   76.099±10.548

###### 

Descriptive statistics for centrality measure of drug therapy studies on major depressive disorder since the 21^st^ century.

  Period      Rank of MeSH terms                                           High-frequency MeSH terms/MeSH subheadings   Centrality   Rank of MeSH terms   High-frequency MeSH terms/MeSH subheadings   Centrality                                                                                                                           
  ----------- ------------------------------------------------------------ -------------------------------------------- ------------ -------------------- -------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------- --------- -------- --------
  2001-2006   1                                                            Depressive Disorder, Major / drug therapy    1321.000     13.055               100.000                                      23                                                           Anxiety Disorders / drug therapy                     87.000    4.037    75.676
  2           Antidepressive Agents / therapeutic use                      836.000                                      13.055       100.000              15                                           Antidepressive Agents / administration & dosage              84.000                                               2.673     68.293   
  4           Serotonin Uptake Inhibitors / therapeutic use                499.000                                      11.642       96.552               26                                           Thiophenes / therapeutic use                                 84.000                                               1.349     66.667   
  5           Antidepressive Agents, Second-Generation / therapeutic use   426.000                                      8.323        87.500               13                                           Antidepressive Agents / adverse effects                      79.000                                               2.773     70.000   
  7           Antidepressive Agents, Tricyclic / therapeutic use           224.000                                      7.926        87.500               18                                           Antidepressive Agents / pharmacology                         70.000                                               3.980     71.795   
  3           Depressive Disorder, Major / therapy                         194.000                                      8.658        87.000               21                                           Antipsychotic Agents / therapeutic use                       67.000                                               1.399     66.667   
  6           Depressive Disorder / drug therapy                           192.000                                      5.687        77.778               27                                           Depressive Disorder, Major / genetics                        67.000                                               1.908     68.293   
  11          Citalopram / therapeutic use                                 189.000                                      2.101        71.795               24                                           Depressive Disorder, Major / complications                   66.000                                               4.847     77.778   
  12          Fluoxetine / therapeutic use                                 184.000                                      4.508        80.000               28                                           Mianserin / analogs & derivatives                            63.000                                               1.966     68.293   
  14          Cyclohexanols / therapeutic use                              183.000                                      4.236        77.778               19                                           Depressive Disorder, Major / metabolism                      62.000                                               3.247     71.795   
  16          Paroxetine / therapeutic use                                 146.000                                      3.799        80.000               25                                           Depressive Disorder, Major / etiology                        55.000                                               0.903     65.116   
  9           Depressive Disorder, Major / psychology                      119.000                                      3.719        77.778               20                                           Depressive Disorder, Major / physiopathology                 55.000                                               2.211     70.000   
  17          Sertraline / therapeutic use                                 118.000                                      1.825        73.684               22                                           Depressive Disorder, Major / blood                           51.000                                               2.393     70.000   
  8           Depressive Disorder, Major / diagnosis                       112.000                                      6.155        80.000               29                                           Depressive Disorder / therapy                                23.000                                               0.000     58.333   
  10          Depressive Disorder, Major / epidemiology                    106.000                                      3.625        77.778               --                                           --                                                           --                                                   --        --       
  2007-2012   1                                                            Depressive Disorder, Major / drug therapy    2471.000     17.598               100.000                                      22                                                           Antidepressive Agents, Tricyclic / therapeutic use   146.000   4.136    79.070
  2           Antidepressive Agents / therapeutic use                      1815.00                                      15.461       97.143               11                                           Antidepressive Agents / pharmacology                         142.000                                              3.964     72.340   
  4           Antidepressive Agents, Second-Generation / therapeutic use   623.000                                      10.759       89.474               15                                           Depressive Disorder, Major / physiopathology                 140.000                                              4.513     75.556   
  5           Serotonin Uptake Inhibitors / therapeutic use                562.000                                      12.658       94.444               26                                           Mianserin / analogs & derivatives                            125.000                                              4.107     75.556   
  7           Citalopram / therapeutic use                                 455.000                                      7.196        87.179               17                                           Antidepressive Agents / administration & dosage              118.000                                              3.062     68.000   
  3           Depressive Disorder, Major / therapy                         412.000                                      10.015       85.000               20                                           Depressive Disorder, Major / blood                           109.000                                              6.497     80.952   
  12          Cyclohexanols / therapeutic use                              349.000                                      5.931        82.927               33                                           Paroxetine / therapeutic use                                 108.000                                              5.242     77.273   
  6           Depressive Disorder, Major / psychology                      289.000                                      12.019       89.474               28                                           Cognitive Behavioral Therapy                                 108.000                                              1.291     66.667   
  10          Depressive Disorder, Major / genetics                        244.000                                      5.620        79.070               31                                           Anxiety Disorders / drug therapy                             99.000                                               2.435     69.388   
  18          Thiophenes / therapeutic use                                 242.000                                      5.242        79.070               27                                           Depression / drug therapy                                    84.000                                               1.963     69.388   
  19          Fluoxetine / therapeutic use                                 241.000                                      4.217        77.273               29                                           Serotonin Uptake Inhibitors / adverse effects                81.000                                               2.161     69.388   
  9           Depressive Disorder, Major / epidemiology                    237.000                                      9.178        87.179               32                                           Cognitive Behavioral Therapy / methods                       70.000                                               0.558     60.714   
  16          Antipsychotic Agents / therapeutic use                       208.000                                      3.594        75.556               23                                           Depressive Disorder, Major / complications                   68.000                                               3.094     69.388   
  8           Depressive Disorder, Major / diagnosis                       196.000                                      8.957        85.000               35                                           Psychotherapy / methods                                      67.000                                               0.555     60.714   
  13          Antidepressive Agents / adverse effects                      166.000                                      4.314        73.913               25                                           Depressive Disorder, Major / metabolism                      53.000                                               1.986     66.667   
  14          Depressive Disorder / drug therapy                           166.000                                      4.713        75.556               34                                           Antidepressive Agents, Second-Generation / adverse effects   49.000                                               1.746     65.385   
  21          Piperazines / therapeutic use                                150.000                                      1.536        69.388               30                                           Depressive Disorder, Major / pathology                       32.000                                               0.059     59.649   
  24          Sertraline / therapeutic use                                 149.000                                      5.628        77.273               --                                           --                                                           --                                                   --        --       
  2013-2018   1                                                            Depressive Disorder, Major / drug therapy    2378.000     18.869               100.000                                      23                                                           Ketamine / therapeutic use                           149.000   1.495    64.815
  2           Antidepressive Agents / therapeutic use                      2059.000                                     17.041       97.222               31                                           Sulfides / therapeutic use                                   147.000                                              0.484     61.404   
  3           Depressive Disorder, Major / therapy                         510.000                                      14.435       94.595               24                                           Brain / drug effects                                         138.000                                              4.971     76.087   
  8           Serotonin Uptake Inhibitors / therapeutic use                361.000                                      11.084       87.500               25                                           Cognitive Behavioral Therapy / methods                       122.000                                              4.199     72.917   
  10          Citalopram / therapeutic use                                 349.000                                      8.026        85.366               16                                           Depressive Disorder, Major / metabolism                      121.000                                              2.995     71.429   
  4           Antidepressive Agents / pharmacology                         342.000                                      12.020       89.744               29                                           Fluoxetine / therapeutic use                                 120.000                                              1.198     66.038   
  5           Depressive Disorder, Major / psychology                      324.000                                      17.486       97.222               18                                           Depressive Disorder, Major / blood                           114.000                                              1.902     68.627   
  9           Antidepressive Agents, Second-Generation / therapeutic use   315.000                                      8.362        83.333               34                                           Cyclohexanols / therapeutic use                              112.000                                              2.797     70.000   
  13          Depressive Disorder, Treatment-Resistant / drug therapy      272.000                                      5.951        77.778               30                                           Outcome Assessment (Health Care)                             107.000                                              4.498     71.429   
  6           Depressive Disorder, Major / diagnosis                       265.000                                      6.067        81.395               21                                           Depressive Disorder / drug therapy                           103.000                                              3.917     68.627   
  7           Depression / drug therapy                                    243.000                                      10.778       83.333               19                                           Depressive Disorder, Major / epidemiology                    94.000                                               2.334     71.429   
  12          Depressive Disorder, Major / genetics                        212.000                                      4.311        72.917               22                                           Depressive Disorder, Major / complications                   91.000                                               3.235     71.429   
  20          Piperazines / therapeutic use                                212.000                                      1.347        66.038               28                                           Ketamine / pharmacology                                      87.000                                               1.778     66.038   
  14          Depressive Disorder, Major / physiopathology                 189.000                                      10.675       85.366               36                                           Suicidal Ideation                                            83.000                                               5.130     79.545   
  11          Antidepressive Agents / administration & dosage              186.000                                      5.262        74.468               35                                           Psychotherapy / methods                                      79.000                                               1.817     67.308   
  17          Antipsychotic Agents / therapeutic use                       165.000                                      4.741        76.087               32                                           Depressive Disorder, Treatment-Resistant / therapy           66.000                                               1.790     63.636   
  15          Antidepressive Agents / adverse effects                      156.000                                      7.341        79.545               27                                           Depressive Disorder, Major / pathology                       55.000                                               0.661     63.636   
  26          Sertraline / therapeutic use                                 152.000                                      3.400        72.917               33                                           Depression / therapy                                         52.000                                               0.603     60.345   

"Rank of MeSH terms" represents the number of high-frequency major MeSH terms/MeSH subheadings in each period as shown in [**Tables 2**](#T2){ref-type="table"}--[**4**](#T4){ref-type="table"}.

###### 

Cluster interpretation of high-frequency major MeSH terms/MeSH subheadings of drug therapy studies on major depressive disorder in PubMed since the 21^st^ century.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Period      Cluster                                                                                                                                                                                                                     Content and interpretation of the cluster                                                                                                                                                                  Rank of MeSH terms                                           Representative literatures (PMID)
  ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ --------------------------------------------------
  2001-2006   Cluster 0                                                                                                                                                                                                                   Application and therapeutic effect of different types of antidepressant agents (TCAs, SSRIs, etc.)                                                                                                         1, 4, 5, 6, 7, 11, 12, 14, 16, 17, 23                        12490825, 15780704, 12027788, 16503815

  Cluster 1   Analysis of influencing factors of the therapeutic effect and clinical outcome (including therapeutic effect and adverse reaction) of antidepressant agents                                                                 2, 3, 8, 9, 10, 25, 26, 29                                                                                                                                                                                 15679210, 12119755, 11497387, 16035056, 14653433, 16356553   

  Cluster 2   Research on the functional mechanism of antidepressants in pathophysiology, neuroendocrinology, and neuro-biochemistry                                                                                                      13, 15, 18, 19, 20, 21, 22, 24, 27, 28                                                                                                                                                                     12478878, 14658930, 11274650, 15774440, 16388723             

  2007-2012   Cluster 0                                                                                                                                                                                                                   Comparative analysis on the clinical treatment effect and tolerability of antidepressant agents (mainly SSRIs and SNRIs) combined with antipsychotics in patients with depressive disorder                 2, 14, 16, 18, 21, 24, 27                                    22813840, 19210951, 17340654, 18164528

  Cluster 1   Analysis of the therapeutic effect of different antidepressant agents (mainly SSRI) on patients with major depressive disorder                                                                                              1, 4, 5, 7, 12, 19, 22, 26, 31, 33                                                                                                                                                                         19345072, 19453203, 18299900                                 

  Cluster 2   Analysis of the therapeutic effect and influencing factors of patients with depressive disorder after receiving psychotherapy (e.g., cognitive therapy, interpersonal psychotherapy) alone, or combined with drug therapy   3, 6, 8, 9, 23, 28, 32, 35                                                                                                                                                                                 19798756, 22985486, 22700618, 19031487                       

  Cluster 3   1\. Explore the causes of adverse reactions of antidepressant agents\                                                                                                                                                       10, 11, 13, 15, 17, 20, 25, 29, 30, 34                                                                                                                                                                     17414739, 21824458, 20393460, 21546222                       
              2. Predictive studies on effectiveness of antidepressant treatment based on brain imaging                                                                                                                                                                                                                                                                                                                                                                                                           

  2013-2018   Cluster 0                                                                                                                                                                                                                   1\. Analysis on the therapeutic effect and influencing factors of patients with depressive disorder after receiving cognitive therapy alone, interpersonal psychotherapy, or combined with drug therapy\   3, 25, 32, 33, 35                                            27236335, 24060588, 27461440, 25093396, 26348032
                                                                                                                                                                                                                                          2. Analysis of the clinical therapeutic effect and cost-effectiveness of different psychotherapy methods                                                                                                                                                                

  Cluster 1   1\. Evaluation of the mechanism of action and therapeutic effect of new antidepressants\                                                                                                                                    1, 2, 7, 13, 17, 20, 23, 31                                                                                                                                                                                25087600, 24676550, 27807822, 24045606, 23442899             
              2. Clinical effect of antipsychotic drugs combined with antidepressant agents                                                                                                                                                                                                                                                                                                                                                                                                                       

  Cluster 2   1\. Analysis of clinical treatment effect of the new antidepressant agents and other SSRIs\                                                                                                                                 8, 9, 10, 12, 21, 26, 29, 34                                                                                                                                                                               23472671, 25815419, 24679400, 26234589                       
              2. Study on genetic/biomarkers that influence the response and efficacy of antidepressant treatment                                                                                                                                                                                                                                                                                                                                                                                                 

  Cluster 3   Effects of antidepressant treatment on residual symptoms of depressed patients and improvement methods                                                                                                                      5, 6, 11, 15, 19, 22, 36                                                                                                                                                                                   26415692, 27500820, 28445632                                 

  Cluster 4   1\. Analysis and research on the mechanism of action and clinical therapeutic effect of antidepressant agents\                                                                                                              4, 14, 16, 18, 24, 27, 28, 30                                                                                                                                                                              26211972, 23271325, 28458140, 23442899                       
              2. Early identification and prevention of suicide attempts and other risky behaviors of depressed patients                                                                                                                                                                                                                                                                                                                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

"Rank of MeSH terms" represents the number of high-frequency major MeSH terms/MeSH subheadings in each period as shown in [**Tables 2**](#T2){ref-type="table"}--[**4**](#T4){ref-type="table"}.

In the first period, during 2001--2006, five MeSH terms (the red and fuchsia circle nodes in [**Figure 7i**](#f7){ref-type="fig"}), including "depressive disorder, major/drug therapy", "antidepressive agents/therapeutic use", "serotonin uptake inhibitors/therapeutic use", "antidepressive agents, second-generation/therapeutic use", "antidepressive agents, and tricyclic/therapeutic use", were shown to have high degree centrality, with values greater than the mean value of 198.690. Among the above five MeSH terms, "depressive disorder, major/drug therapy" had the highest degree centrality at 1312.000 ([**Table 6**](#T6){ref-type="table"} and [**Figure 7**](#f7){ref-type="fig"}). In addition, given that the size of a node of an SNA is measured by its betweenness centrality, we found that the MeSH terms "depressive disorder, major/drug therapy", and "antidepressive agents/therapeutic use" displayed the highest same value of betweenness centrality of 13.055 and the highest same value of closeness centrality of 100.000 ([**Table 6**](#T6){ref-type="table"}). The results indicated that the above terms not only played the most significant mediating role, but also had a tight connection with other nodes in the SNA during 2001--2006. Meanwhile, as shown in [**Table 5**](#T5){ref-type="table"}, another seven MeSH terms, including "serotonin uptake inhibitors/therapeutic use", "antidepressive agents, second-generation/therapeutic use", "antidepressive agents, tricyclic/therapeutic use", "depressive disorder, major/therapy", "depressive disorder/drug therapy", "depressive disorder, major/diagnosis", and "depressive disorder, major/complications" displayed higher betweenness centrality whose values of betweenness degree were greater than the mean value of 4.552 ([**Table 5**](#T5){ref-type="table"}). Furthermore, 13 MeSH terms (lime square nodes in [**Figure 7i**](#f7){ref-type="fig"}), such as "depressive disorder, major/physiopathology", "antipsychotic agents/therapeutic use", "depressive disorder, major/etiology", "depressive disorder, major/genetics", "citalopram/therapeutic use", "cyclohexanols/therapeutic use", "sertraline/therapeutic use", "depressive disorder/therapy", "depressive disorder, major/blood", "antidepressive agents/adverse effects", "thiophenes/therapeutic use", "antidepressive agents/administration & dosage", and "antidepressive agents/pharmacology" were emerging hotspots, which were located on the edge of the SNA during 2001--2006.

As in the first time-period, the MeSH term "depressive disorder, major/drug therapy" still had the highest value of degree centrality (2471.000, [**Table 6**](#T6){ref-type="table"} and [**Figure 7ii**](#f7){ref-type="fig"}) during 2007--2012. Expect for the four MeSH terms (the red and fuchsia red nodes in [**Figure 7ii**](#f7){ref-type="fig"}) with high values of degree centrality in 2001--2006, another three MeSH terms (yellow circle nodes in [**Figure 7ii**](#f7){ref-type="fig"}) "citalopram/therapeutic use", "depressive disorder, major/therapy", and "cyclohexanols/therapeutic use" displayed higher degree centrality, with values greater than the mean value of 302.114 ([**Table 5**](#T5){ref-type="table"}). Whereas, 13 MeSH terms, including "depressive disorder, major/drug therapy", "antidepressive agents/therapeutic use", "antidepressive agents, second-generation/therapeutic use", "serotonin uptake inhibitors/therapeutic use", "citalopram/therapeutic use", "depressive disorder, major/therapy", "cyclohexanols/therapeutic use", "depressive disorder, major/psychology", "depressive disorder, major/genetics", "depressive disorder, major/epidemiology", "depressive disorder, major/diagnosis", "sertraline/therapeutic use", as well as "depressive disorder, major/blood", displayed higher betweenness centrality (greater than the mean value of 5.486, [**Table 5**](#T5){ref-type="table"}). In addition, the newly nine emerging hotspots (purple square nodes in [**Figure 7ii**](#f7){ref-type="fig"}) were located on the edge of the SNA during 2007--2012, including "antidepressive agents, second-generation/adverse effects", "serotonin uptake inhibitors/adverse effects", "depressive disorder, major/metabolism", "depressive disorder, major/pathology", "cognitive behavioral therapy/methods", "depression/drug therapy", "piperazines/therapeutic use", "anxiety disorders/drug therapy", and "psychotherapy/methods'.

Finally, according to statistical analysis, the MeSH term "depressive disorder, major/drug therapy" still had the greatest value of degree centrality during 2013--2018, similar to the two previous time-periods. In addition, six new major MeSH terms/MeSH subheadings were added to the nodes of the SNA during 2013--2018 ([**Figure 7iii**](#f7){ref-type="fig"}, including "antidepressive agents/pharmacology", "depressive disorder, treatment-resistant/drug therapy", "depressive disorder, major/diagnosis", "depression/drug therapy", "depressive disorder, major/physiopathology", and "antidepressive agents/adverse effects", which were characterized by higher value of betweenness centrality (greater than the mean value of 5.917, [**Table 5**](#T5){ref-type="table"}). Furthermore, compared with the first and second time-periods of the SNA ([**Figure 7**](#f7){ref-type="fig"}), a total of eight new emerging nodes (aqua square nodes in [**Figure 7iii**](#f7){ref-type="fig"}), including "sulfides/therapeutic use", "brain/drug effects", "ketamine/therapeutic use", "ketamine/pharmacology", "depressive disorder, treatment-resistant/therapy", "depression therapy", "depressive disorder, major/epidemiology", and "fluoxetine/therapeutic use", were considered as emerging hotspots of drug therapy studies on MDD during 2013--2018.

Discussion {#s4}
==========

Antidepressants are medications that can help relieve symptoms of depression, seasonal affective disorder, dysthymia, and mild chronic depression, as well as other conditions. These medications were first developed in 1950 and their use has become progressively more common ([@B11]), with approximately 70% of patients responding positively to at least one antidepressant ([@B50]). This study evaluated drug therapy studies on MDD in recent decades by exploring bibliometrics to reach the conclusion that publication related to the topic increased, with varying degrees of fluctuation, in the last 18 years since the beginning of the 21^st^ century. Moreover, after in-depth analysis, we observed that growth of publications during the third period of 2013-2018 slowed in comparison with the second period, and there was a slight decline in 2005, 2011, and 2016 (one in every period studied). In addition, consistent with the results of bibliometric analysis in other research fields, we found that the U.S. and England were the top two countries contributing the most to drug therapy studies on MDD ([@B51], [@B52]). This result is likely related to the fact that PubMed mainly includes articles written in English; that the first official language in these two countries is English; and that government support for scientific research funding and of influential scientists, among other factors, is prominent in both countries ([@B52]). However, based on the results of the strategic diagram, we observed that the contents of the theme clusters in each quadrant changed, to some extent, so that we have a preliminary understanding of theme trends from 2001 to 2018.

In the first period of 2001--2006, cluster 2 situated in quadrant III indicated that research on the functional mechanism of antidepressants in pathophysiology, neuroendocrinology, and neuro-biochemistry was immature and needed further study. We found that previous research qualitatively analyzed the degree of striatal dopamine and serotonin receptors/transporter occupancy by using technologies, including single photon emission computerized tomography and positron emission tomography to study the efficacy and side effect profile of antipsychotics, which provided evidence to uncover the pathophysiology mechanism of depressive disorder and other neuropsychiatric disorders ([@B53]). In addition, scholars propose that depressed patients suffer from a reduced number and/or function of glucocorticoid receptors (GR), and that antidepressants can exert therapeutic action by enhancing GR function expression ([@B54]). These findings further elucidate the biochemical and molecular mechanisms of MDD and lead to a new insight into the pathophysiology and treatment of the disease ([@B54]). However, due to the complex, and as of yet controversial, pathogenesis of MDD, mechanisms involved in its progression are only beginning to be elucidated. At the same time, studies on the development, mechanism of use, clinical application, and evaluation of antidepressant drugs against MDD are also increasing. Moreover, as antidepressant treatment based on the traditional monoamine theory results in delayed and high treatment inefficiency ([@B55]), scholars have been committed to the improvement of traditional antidepressants and to the discovery of new therapeutics that target the functional mechanisms of the disease.

Additionally, cluster 1 located in quadrant IV indicated that the influencing factors of therapeutic effect and clinical outcome of antidepressant agents were in immature stages of research development and needed further study. Previous reports had suggested that the knowledge and attitude of doctors toward the diagnostic criteria for depressive disorders ([@B56]), and the age, genotype, medical burden, physical and psychiatric symptoms, and alcohol consumption of the patients with MDD before treatment ([@B57]--[@B59]), could have a significant impact on the course and outcome of antidepressant medication. However, the genome, gender, medication compliance, and suicide ideation degree of the depressed patients also need to be taken into account when prescribing the different types and dosages of antidepressants ([@B60]--[@B62]). Subsequent research needs to integrate the above factors and to carry out in-depth discussion regarding the results.

During 2007--2012, cluster 2 located in quadrant III indicated that researchers focused on the topic of therapeutic effect and influencing factors of depressed patients after receiving psychotherapy alone, or combined with drug therapy. Psychological treatment (e.g., cognitive therapy and interpersonal psychotherapy), as the most common nonpharmacological intervention combined with pharmacotherapy, aims to enhance efficacy, to improve patients' social functioning and QOL, and to prevent or delay recurrence. Previous studies have shown that the combination of psychological and pharmacological treatment is somewhat more effective than treatment with pharmacotherapy alone ([@B63]). Meanwhile, the results of a meta-analysis based on 18 studies and 1,838 subjects showed that a combined treatment was more effective than psychological treatment alone, especially for specific populations of older adults with chronic depression ([@B64]). However, these results need further verification by follow-up investigation in clinic. In addition, except for patient's preference and compliance for treatment methods, the doctor-patient relationship, patients' lifestyle, and other influencing factors need to be further explored ([@B65]). Clusters 2 and 3 were both the in quadrant III and had the same theme content; predictive studies on the effectiveness of antidepressant treatment based on brain imaging. Functional connectivity between the pregenual anterior cingulate cortex and the left amygdala is known to be negatively correlated with changes in antidepressant symptoms among patients with MDD ([@B66]). Scholars need to overcome current limitations where pre-treatment brain imaging can only explain what features are more likely to improve early symptoms, but not specific early and progressive changes in brain imaging of patients after drug therapy ([@B67]).

Anxiety is responsible for a reduction in the efficacy of antidepressant treatment. However, in contrast to the results of cluster 0 during 2001--2006 ([@B68]), the results of cluster 1 in the second phase of 2007-2012 demonstrated that escitalopram was better than paroxetine for highly depressed patients with comorbid anxiety symptoms ([@B69]). Another difference in the results of cluster 0 was that researchers not only focused on antidepressant only use ([@B70]), but were now more likely to evaluate and to prescribe antidepressants combined with antipsychotics ([@B71]). However, the evaluation of the specific treatment model, safety, tolerability and other factors of multi-drug combinations still need to be further improved.

During 2013--2018, cluster 1, with theme contents involved in the evaluation of the mechanism of action and therapeutic effect of new antidepressants, was located in quadrant I. Pearce et al. analyzed the mechanism of action of the new antidepressant agent vortioxetine and proposed it was an effective agent for the treatment of MDD ([@B72]). Afterwards, vortioxetine and agomelatine, as new antidepressant drugs, were respectively used for MDD patients with inadequate responses to SSRI/SNRI monotherapy. The authors were able to show that vortioxetine was safer and better tolerated by employing the clinical outcome indicators of changes in depression and anxiety symptoms, response and remission rates, QOL, productivity, and family functioning ([@B73]). In addition, for patients with MDD who are non-responsive or partially responsive to one or more antidepressants, researchers proposed that adjunctive therapy with atypical antipsychotics (e.g., aripiprazole) to be efficacious and well tolerated ([@B74]). The data indicate that, based on clinical empirical research, MDD patients who are difficult to treat have received extensive attention from researchers, which has resulted in better treatment options.

Furthermore, the theme contents of clusters 2--4, situated in quadrant III, were peripheral and undeveloped in the research field of drug therapy studies on MDD during the past 6 years of 2013--2018. Due to the demographic factors of patients, there may be differences in the effectiveness of drug treatments and onset of adverse reactions, leading to the progression or even deterioration of the disease ([@B75]). Therefore, researchers need to develop more antidepressants with rapid-onset that are safe and have fewer side effects. At present, ketamine, an antagonist of the N-methyl-D-aspartate family of glutamate receptors, has shown rapid antidepressant effectiveness in patients with MDD in clinic ([@B76]). However, given that ketamine's specific mechanism of action is still in the theoretical hypothesis stage and that there are safety issues surrounding its use, the drug has not been used extensively as an antidepressant ([@B77]). Meanwhile, due to the existence of various complex pathways in the nervous system and negative feedback regulation mechanisms, research and development of single target therapy and mono-medication treatments have encountered a bottleneck. Thus, multi-target synergistic and combinatory drugs will become the main-line treatment in the future. In addition, genome-wide genotyping technology has made some progress in the study of genetic/biomarkers influencing the response and efficacy of antidepressant treatment, but due to the complexity of the pathogenesis of MDD, research still needs to be further improved ([@B78]). Moreover, scholars analyzed the mechanism of action and clinical therapeutic effect of antidepressant agents from two perspectives: the interaction between synaptic generation and neurogenesis ([@B79]), and the changes in the functional connections of multiple brain regions in patients with depressive disorder ([@B80]). However, relevant research conclusions have been based on the combination of multiple studies, and future research should generate a common and standardized strategy for data acquisition and statistical analysis to establish a scientifically and clinically useful and unified knowledge network by eliminating method bias as much as possible.

Finally, we can also conclude that the MeSH terms depressive disorder, major/drug therapy, and antidepressive agents/therapeutic use have the highest values of betweenness centrality, implying that they have the largest number of direct connections with other nodes, and that they are located at the core position within the SNAs. In other words, research on the functional mechanism of antidepressants; therapeutic effect and influencing factors of depressed patients after receiving single psychotherapy or combined with drug therapy; predictive studies on effectiveness of antidepressant treatment based on brain imaging; genetic/biomarkers that influence the response and effect of antidepressant treatment; antidepressant treatment on residual symptoms of depressed patients and improvement methods; and mechanism of action and clinical therapeutic effect of antidepressant agents are significant and potentially important academic issues in the field of MDD research. In addition, the new emerging hotspots during the three periods of 2001--2006, 2007--2012, and 2013--2018 studied should be viewed as a guide to finding new directions for research. Another emerging theme content was in regards to identification and medical intervention of MDD patients with suicide attempts, focusing on the analysis and extraction of the variables relevant to suicide attempts, and the impact of basic suicide tendency on the effect of antidepressants ([@B8], [@B81]). Specific medication intervention measures need to be further studied.

Conclusions {#s5}
===========

According to analyze the publications in each period from 2001 to 2008, we can conclude that drug therapy studies on MDD have been a significant issue of general concern, but that progress has relatively slowed in recent six years. By integrating methods of bi-clustering, strategic diagram and SNAs analysis, the more significant findings of this study revealed the undeveloped theme clusters in recent decades, such as therapeutic effects of drug therapy in patients with MDD based on brain imaging, genetic/biomarkers affecting the response and efficacy of antidepressants, as well as mechanisms of adverse reaction of antidepressants. Furthermore, emerging MeSH terms/hotspots, such as antidepressive agents/administration & dosage, antidepressive agents/adverse effects, brain/drug effects also could provide medical staff, scientific researchers, and frontline educators with new research topics in the field of drug therapy studies on MDD.

Limitation {#s5_1}
----------

There are several limitations in the current study: First, the data collection was only limited to papers that were published in PubMed which have led to publication bias to some extent. Second, considering that high-impact journals also have a high standard for the articles they include, the number of papers on the same research topic published in high-impact journals is limited, and many more may have been published in other relatively low-impact journals. Therefore, the extracted literature from different types of journals may contribute different weights to the formation of knowledge structure and the prediction of theme trends. Third, we carried out co-word analysis on the basis of extracting high-frequency MeSH terms/MeSH subheading by BICOMBS, which may have led to several new emerging subjects with low attention being missed due to a low word frequency that was below the threshold value of high-/low-frequency major MeSH terms/MeSH subheadings. Therefore, bibliometric analysis should be a dynamic process, and relevant results and conclusions should be further updated and improved through an increase in database sources and the extension of research time.
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